Posted On: 03/03/2016 9:07:37 AM
Post# of 72447
This is on TDAmeritrade news feed today
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Company Profiles discussed in this report includes Ability Pharma, SL, Acceleron Pharma, Inc., Advenchen Laboratories, LLC, Aeterna Zentaris Inc., Arno Therapeutics, Inc., ArQule, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., BeiGene(Beijing) Co.,Ltd, Boehringer Ingelheim GmbH, Cellceutix Corporation, Critical Outcome Technologies Inc., Eisai Co., Ltd., Eli Lilly and Company, Esperance Pharmaceuticals, Inc., Exelixis, Inc., Galena Biopharma, Inc., Genmab A/S, GlaxoSmithKline Plc, Gradalis Inc., ImmunoGen, Inc., Incyte Corporation, Karyopharm Therapeutics, Inc., Medivation, Inc., Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Inc., Novartis AG, OncoHoldings, Inc., Oncothyreon Inc., Otsuka Holdings Co., Ltd., Pharma Mar, S.A., Pharmsynthez, Puma Biotechnology, Inc., Sanofi, Scancell Holdings Plc and Shenogen Pharma Group Ltd. Complete report on H2 2015 pipeline review of Endometrial Cancer with 57 market data tables and 16 figures, spread across 280 pages is available at http://www.reportsnreports.com/reports/453485...-2015.html .
Drugs Profiles discussed in this report includes Pb-TCMC-Trastuzumab, ABTL-0812, AEZS-125, AL-3818, ARQ-092, AV-203, AZD-2014, AZD-5363, BGB-283, buparlisib hydrochloride, cabozantinib s-malate, cancer vaccine, Cell Therapy for Ovarian and Endometrial Cancer, Cell Therapy to Target HER-2 for Oncology, CLR-457, COTI-2, cridanimod, dalantercept, EP-200, epacadostat, everolimus, GALE-301, GSK-2636771, HO-3867, HuMax-TF-ADC, INCB-54828, KM-3174, lenvatinib, lurbinectedin, LY-3023414, mirvetuximab soravtansine, MK-2206, Modi-1, Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer, neratinib, nintedanib, onapristone ER, ONCO-101, ONT-10, OPB-111001, Peptides to Inhibit GnRH II Receptor for Oncology, pimasertib hydrochloride + voxtalisib, sapanisertib, SAR-408701, selinexor, Small Molecules to Inhibit Skp2 for Endometrial Cancer and Melanoma, SNG-1153, SP-2509, talazoparib, trametinib dimethyl sulfoxide + uprosertib, X-480 and zoptarelin doxorubicin.
Order a Purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=453485 .
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Company Profiles discussed in this report includes Ability Pharma, SL, Acceleron Pharma, Inc., Advenchen Laboratories, LLC, Aeterna Zentaris Inc., Arno Therapeutics, Inc., ArQule, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., BeiGene(Beijing) Co.,Ltd, Boehringer Ingelheim GmbH, Cellceutix Corporation, Critical Outcome Technologies Inc., Eisai Co., Ltd., Eli Lilly and Company, Esperance Pharmaceuticals, Inc., Exelixis, Inc., Galena Biopharma, Inc., Genmab A/S, GlaxoSmithKline Plc, Gradalis Inc., ImmunoGen, Inc., Incyte Corporation, Karyopharm Therapeutics, Inc., Medivation, Inc., Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Inc., Novartis AG, OncoHoldings, Inc., Oncothyreon Inc., Otsuka Holdings Co., Ltd., Pharma Mar, S.A., Pharmsynthez, Puma Biotechnology, Inc., Sanofi, Scancell Holdings Plc and Shenogen Pharma Group Ltd. Complete report on H2 2015 pipeline review of Endometrial Cancer with 57 market data tables and 16 figures, spread across 280 pages is available at http://www.reportsnreports.com/reports/453485...-2015.html .
Drugs Profiles discussed in this report includes Pb-TCMC-Trastuzumab, ABTL-0812, AEZS-125, AL-3818, ARQ-092, AV-203, AZD-2014, AZD-5363, BGB-283, buparlisib hydrochloride, cabozantinib s-malate, cancer vaccine, Cell Therapy for Ovarian and Endometrial Cancer, Cell Therapy to Target HER-2 for Oncology, CLR-457, COTI-2, cridanimod, dalantercept, EP-200, epacadostat, everolimus, GALE-301, GSK-2636771, HO-3867, HuMax-TF-ADC, INCB-54828, KM-3174, lenvatinib, lurbinectedin, LY-3023414, mirvetuximab soravtansine, MK-2206, Modi-1, Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer, neratinib, nintedanib, onapristone ER, ONCO-101, ONT-10, OPB-111001, Peptides to Inhibit GnRH II Receptor for Oncology, pimasertib hydrochloride + voxtalisib, sapanisertib, SAR-408701, selinexor, Small Molecules to Inhibit Skp2 for Endometrial Cancer and Melanoma, SNG-1153, SP-2509, talazoparib, trametinib dimethyl sulfoxide + uprosertib, X-480 and zoptarelin doxorubicin.
Order a Purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=453485 .
(1)
(0)
